Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  News


Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Zogenix Inc. : Zogenix Announces Conference Call and Webcast to Present First Quarter 2013 Financial Results

05/03/2013 | 08:40am US/Eastern
Conference Call Scheduled for May 9, 2013 at 4:30 pm ET

SAN DIEGO, May 3, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release financial results for the first quarter ended March 31, 2013, after the market closes on Thursday, May 9, 2013, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these financial results and provide a company update.

To access the live webcast please visit the Company's Investor Relations website at ir.zogenix.com, and to participate, please dial (866) 318-8616 (U.S.) or (617) 399-5135 (International); participant passcode: 65838569.

The conference call will be hosted by Chief Executive Officer Roger L. Hawley, President Stephen J. Farr, Ph.D., and Executive Vice President and Chief Financial Officer Ann Rhoads.

A replay of the conference call will be available beginning May 9, 2013 at 6:30 p.m. ET (3:30 p.m. PT) until May 16, 2013, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 23471504. A replay of the webcast will also be accessible on the Investor Relations website for one month, through June 9, 2013.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, Zohydro™ ER (hydrocodone bitartrate), is an oral, extended-release formulation of various strengths of hydrocodone, without acetaminophen, intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER. Zogenix's second investigational product candidate, Relday™, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia; an investigational new drug application was submitted to the FDA in May 2012. For additional information, please visit www.zogenix.com.

         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         Caitlin Cox | The Ruth Group
         646.536.7033 | ccox@theruthgroup.com
distributed by
React to this article
Latest news
Date Title
04:12p FITLIFE BRANDS : and iSatori, Inc. Announce Exchange Ratio for Merger
04:12p Patent Issued for Transmission and Reception System, Transmitting and Receiving Unit, and Transmitting and Receiving Method (USPTO 9148750)
04:12p Patent Issued for Dental Adhesive Agent for High-Performance Polymers (USPTO 9144533)
04:11p VISION EYE INSTITUTE : Group debuts digital versions for newspapers
04:11p DOMTAR : Uses 75% Renewable Energy in its Pulp and Paper Manufacturing
04:11p PROGRESS SOFTWARE : Reports 2015 Fiscal Third Quarter Results
04:11p Patent Issued for Driving Analysis Using Vehicle-To-Vehicle Communication (USPTO 9147353)
04:11p KIMCO REALTY : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
04:11p GOLUB CAPITAL BDC : Announces $187.4 Million In New Middle-Market Originations For Its Fiscal Year 2015 Fourth Quarter
Latest news
Hot News 
MAX PETROLEUM : Notice of General Meeting
UBS : Credit Suisse and the Banques Cantonales Latines agree on a certification standard for client advisors
6D GLOBAL TECHNOLOGIES : Rosen Law Firm Announces Investigation of Securities Claims Against 6D Global Technologies, Inc.
JOURNAL MEDIA : Gannett to Acquire Journal Media Group for $12.00 per share
MEDCOMTECH : CONTRACT AWARD - 65-- Covidien Lung Testing Kit - BRAND NAME
Most Read News
01:01a Treatment Effects Maintained Over Five Years in Majority of Patients with Relapsing Remitting Multiple Sclerosis who Received Genzyme’s Lemtrada® (alemtuzumab) in Clinical Trials
10/07 Super Nova Holding an Annual General and Special Meeting on November 18, 2015
10/07 Mike Cegelski Wins Angel of the Year, Presented by BDC Capital
06:31a VG LIFE SCIENCES : Notes Major Achievements and New Grants in Third Quarter 2015
10/07 MCLANE : Topper Retires From CrossAmerica
Most recommended articles
04:09p No room for mistakes by central banks amid 'new mediocre'
04:08pDJUSDA Afternoon National Slaughter Cattle Review - Oct 8
04:06p TSX rallies for fifth session as oil surge fuels energy stocks
04:05p Dovish Fed drives Wall Street higher
04:04pDJU.S. Treasury Yields Hit October Highs